Indoleamine 2,3-dioxygenase (IDO) enzyme inhibitors have entered clinical trials for cancer treatment based on preclinical studies, indicating that they can defeat immune escape and broadly enhance other therapeutic modalities. However, clear genetic evidence of the impact of IDO on tumorigenesis in physiologic models of primary or metastatic disease is lacking. Investigating the impact of Ido1 gene disruption in mouse models of oncogenic KRAS-induced lung carcinoma and breast carcinoma-derived pulmonary metastasis, we have found that IDO defi ciency resulted in reduced lung tumor burden and improved survival in both models. Micro-computed tomographic (CT) imaging further revealed that the density of the underlying pulmonary blood vessels was signifi cantly reduced in Ido1-nullizygous mice. During lung tumor and metastasis outgrowth, interleukin (IL)-6 induction was greatly attenuated in conjunction with the loss of IDO. Biologically, this resulted in a consequential impairment of protumorigenic myeloid-derived suppressor cells (MDSC), as restoration of IL-6 recovered both MDSC suppressor function and metastasis susceptibility in Ido1-nullizygous mice. Together, our fi ndings defi ne IDO as a prototypical integrative modifi er that bridges infl ammation, vascularization, and immune escape to license primary and metastatic tumor outgrowth.
INTRODUCTION
Infl ammatory tissue microenvironments contribute strongly to tumor progression, but due to the complex multifactorial nature of infl ammation, there remains limited understanding of specifi c pathogenic components that might be targeted to effectively treat cancer (1) . In this context, the tryptophancatabolizing enzyme indoleamine 2,3-dioxygenase (IDO) has emerged as an intriguing target implicated in tumoral immune escape (2, 3) . IDO-inhibitory compounds have entered clinical trials based on evidence of immune-based antitumor responses in a variety of preclinical models of cancer (4) (5) (6) (7) (8) (9) (10) . Meanwhile, inadvertent IDO targeting may already be providing benefi ts to patients as illustrated by recent evidence that the clinically approved tyrosine kinase inhibitor imatinib dampens IDO induction as a key mechanism for achieving therapeutic efficacy in the treatment of gastrointestinal stromal tumors (11) .
Although results with IDO pathway inhibitors are provocative, the conclusions that can be drawn are inherently limited by drug specifi city concerns, especially in the absence of independent genetic validation. Addressing this issue, our studies on the impact of Ido1 gene deletion on 7,12-dimethylbenz(a) anthracene/12-O-tetradecanoylphorbol-l3-acetate (DMBA/TPA)-elicited skin papillomagenesis established that IDO has an integral tumor-promoting role in the context of phorbol ester-elicited infl ammation (12, 13) , but interpretation of these results is tempered by the possibility that the chemical exposures in this model may produce anomalies irrelevant to the majority of spontaneous tumors. The lungs present a particularly compelling physiologic context in which to further investigate the role of IDO in tumorigenesis as IDO is known to be highly inducible in this tissue (14, 15) , and there is an urgent unmet medical need for effective therapeutic options to treat primary lung tumors and metastases. In this report, we investigated the consequences of IDO loss through genetic ablation in the context of well-established, pulmonary models of oncogenic KRAS-induced adenocarcinoma and orthotopic breast carcinoma metastasis. Our fi ndings reveal previously unappreciated roles for IDO in vascularization and in the production of the proinfl ammatory cytokine interleukin (IL)-6 that in turn dictates the development of protumorigenic, myeloid-derived suppressor cells (MDSC). A, Kaplan-Meier survival curves for cohorts of Lox-Kras G12D (n = 23) and Ido1 −/− Lox-Kras G12D (n = 14) mice infected with 2.5 × 10 7 plaque-forming units (pfu) of Ad-Cre virus. B, Kaplan-Meier survival curves for cohorts of Lox-Kras G12D (n = 8) and Ido1 −/− Lox-Kras G12D (n = 5) mice infected with 1.25 × 10 8 pfu Ad-Cre virus. Signifi cance for both data sets was assessed by 2-group log-rank test at P < 0.05. C, total lung DNA prepared from 3 mice per time point was analyzed for the presence of the viral Cre gene by real-time PCR at 0, 1, 3, and 7 days postinfection. Relative Cre levels determined from this analysis are plotted as means ± SEM. D, representative hematoxylin and eosin (H&E)-stained sections depicting the observed difference in early lesions between the lungs of Lox-Kras G12D and Ido1 −/− Lox-Kras G12D mice at 6 weeks postinfection. E, quantitative histopathologic assessment of lesion frequency in H&E-stained sections of lung biopsies from Lox-Kras G12D and Ido1 −/− Lox-Kras G12D mice at 6 and 12-week postinfection (n ≥ 5). The number of lesions identifi able under low magnifi cation within a defi ned region of each specimen are graphed on the scatter plot with the means ± SEM. Signifi cance was determined by 2-tailed Student t test at P < 0.05. NS, not signifi cant.
(Ad-Cre) to activate the latent oncogenic Kras G12D allele (16) . These RAS-induced adenocarcinomas elicit a robust infl ammatory response (17) wherein IDO may impart a protumorigenic skew (2 (Fig. 1A and B) . Similar levels of Cre were present in the lungs of both strains at 0, 1, 3, and 7 days postinfection (Fig. 1C) . Unexpectedly, histopathologic examination at 6 weeks revealed that the frequency of early precancerous lesions was actually about 3-fold higher in the Ido1 −/− Lox-Kras G12D mice ( Fig. 1D and E Supplementary Fig. S1A ). While early tumorigenesis may be negatively impacted by IDOmediated tryptophan catabolism, as previously proposed (19) , this phenomenon was transient with the differential no longer signifi cant by 12 weeks (Fig. 1E ).
IDO Defi ciency Impairs Tumor Outgrowth and Vascular Development in the Lung
To assess the impact of Ido1 loss on overt lung tumors, noninvasive micro-computed tomographic (CT) scans were conducted on groups of Lox-Kras G12D and Ido1 −/− Lox-Kras G12D mice at 18 and 24 weeks following Ad-Cre administration ( Fig. 2A) . CT images and 3D reconstructions of Lox-Kras G12D and Ido1 −/− Lox-Kras G12D mouse lungs acquired at 0, 18, and 24 weeks postinfection. Tumor and vasculature, which have indistinguishable x-ray densities, are designated in red in the individual CT images (left) or red/orange for exterior/interior location in the 3D reconstructions (right). B, volumetric image analysis of tumor and vasculature conducted on the 3D reconstructions of lung micro-CT images. The data are graphed as a scatter plot with the means ± SEM (Δ; fold difference). Signifi cance was determined by 2-tailed Student t test at P < 0.05. C, immunofl uorescent staining of blood vessels with antibody to caveolin 1 (red) and 4′,6-diamidino-2-phenylindole (DAPI) staining of nuclei (blue) in representative lung tissue specimens from BALB/c WT and Ido1 −/− mice. D, quantitation of blood vessel areas. The vessel area totals measured within each fi eld are graphed as a scatter plot with the means ± SEM (Δ; fold difference). Signifi cance was determined by 2-tailed Student t test at P < 0.05. E, distribution of pulmonary vessels within specifi ed size ranges. The total number of small (<500 μm 
RESEARCH ARTICLE
Semiautomated quantitative image analysis (20) was conducted on 3-dimensional (3D) reconstructions of the thoracic cavity excluding the heart to assess the combined tumor and vasculature volume within this space. Although lung tumor burden did increase progressively in both cohorts, it was signifi cantly reduced in the Ido1 −/− Lox-Kras G12D mice relative to the corresponding Ido1-competent Lox-Kras G12D mice (Fig. 2B) . Individual micro-CT scan images paired with 3D reconstructions of total chest space and functional lung volume visually highlight the difference in lung tumor burden between representative Ido1 G12D and Kras G12D animals ( Fig. 2A ; Supplementary Videos). These results indicate that IDO defi ciency mitigates overt lung tumor outgrowth, consistent with the increased survival exhibited by these mice.
Lox-Kras
Micro-CT analysis additionally revealed that the density of normal vasculature in the lungs of uninfected animals was substantially diminished in the Ido1 −/− animals ( Fig. 2A and B) .
Intriguingly, the difference in vascular density between IDOdefi cient and IDO-competent cohorts was proportionately comparable with the difference in overt lung tumor burden at the 18-and 24-week time points ( Supplementary Fig. S1B ), suggesting an association between the extent of the underlying basal vasculature and the capacity of the lungs to support tumor formation. Immunofl uorescent staining of blood vessels in the lungs confi rmed the decrease in pulmonary vascular density in Ido1 −/− animals (Fig. 2C) . The area within the lungs occupied by vessels was reduced by about 1.6-fold in Ido1 −/− animals ( Fig. 2D ), in line with the differential identifi ed by micro-CT data analysis. Further analysis revealed that the reduction in vascular density occurred predominantly at the level of small-to medium-sized vessels, which were nearly twice as abundant in the wild-type (WT) animals, whereas there was little difference in the number of large vessels ( Fig. 2E ; Supplementary Fig. S1C ).
IDO Promotes IL-6 Elevation during Lung Tumor Formation
In the lungs, IDO is highly responsive to pathogen or cytokine exposure (14, 15) . To determine whether lung tumorigenesis also stimulates IDO, we compared steady-state levels of the tryptophan catabolite kynurenine at various times after Kras G12D activation. Although baseline levels of kynurenine in the lungs of uninfected Lox-Kras G12D mice were signifi cantly higher than in their IDO-defi cient counterparts (Fig. 3A) , these levels remained constant during lung tumorigenesis (Fig. 3A) . In contrast, a multiplexed analysis of infl ammatory cytokines at 19 and 26 weeks revealed IL-6 to be elevated by about 25-and 68-fold, respectively, in lungs from tumor-bearing Lox-Kras G12D mice but only by about 1-and 3-fold in Ido1 −/− Lox-Kras G12D mice (Fig. 3B ). This fi nding was notable given the known tumor-promoting role of IL-6 in this model (21) . Although not of the same magnitude, induction of CCL2/MCP1 [chemokine (C-C motif) ligand 2] was likewise attenuated in tumor-bearing Lox-Kras G12D mice lacking Ido1 (Fig. 3C ). In contrast, Ido1 loss did not signifi cantly affect the relative levels of IL-10, IFN-γ, TNF-α, or IL-12p70 (data not shown).
IDO Defi ciency Impedes the Development of Pulmonary Metastases
Given the evidence that Ido1 −/− mice are resistant to the outgrowth of primary lung tumors, we asked whether Ido1
animals might exhibit reduced susceptibility to pulmonary metastasis development as well. This question was investigated by orthotopic engraftment of mice with highly malignant 4T1 breast carcinoma cells, which metastasize effi ciently to the lungs. Survival was increased signifi cantly in Ido1
hosts compared with WT hosts after challenge with either a 4T1-luciferase-expressing subclone or with parental 4T1 cells, despite an overall shift in the curves ( −/− mice following orthotopic engraftment of 1 × 10 4 (A) 4T1-luc (n = 25) or (B) 4T1 (n ≥ 9) tumor cells. Signifi cance was assessed by 2-group log-rank test at P < 0.05. The survival benefi t observed in Ido1 −/− mice was independently replicated at University of Maryland Baltimore County. C, staining of lungs with India ink and axial images from micro-CT scans depicting the difference in pulmonary metastasis burden between WT and Ido1 −/− mice at 5 weeks following orthotopic 4T1 tumor cell engraftment. At 5 weeks following (D) orthotopic engraftment of 4T1 cells (n = 6) or (E) orthotopic engraftment of 4T1 cells and resection of the primary tumor at 18 days postengraftment (n ≥ 11), colony-forming assays were conducted to assess the relative tumor cell burden in the blood (neat) and lungs (1:1,000). Individual data points are graphed on a log scale scatter plot with the means ± SEM and signifi cance assessed by 2-tailed Student t test at P < 0.05 (NS, not signifi cant). no difference in metastatic burden was observed in liver, although the presence of 4T1 cells was also nearly too low to detect in this tissue ( Supplementary Fig. S2C ). Because excision of the primary tumor can alter immune-based effects on metastasis (23), we evaluated the metastasis burden in resected mice. Ido1 −/− mice continued to exhibit signifi cant resistance to metastasis development (Fig. 4E ), indicating that IDO-mediated support of metastatic development in lung is not dependent on the presence of the primary tumor. We also examined pulmonary VEGF levels but found that these increased comparably in both WT and Ido1 −/− lungs during metastasis development and were actually somewhat higher at baseline in the Ido1 −/− lungs ( Supplementary   Fig. S2D ).
IDO Is Activated during Metastatic Lung Colonization and Potentiates IL-6 Induction
In WT mice, IDO1 protein and kynurenine levels both increased in the lungs during 4T1 metastasis development, particularly at 5 and 6 weeks postengraftment ( Fig. 5A and B) . The principal source of IDO1 expression in this context appears to be the native stroma rather than the engrafted 4T1 tumor cells because no IDO1 protein was detectable in the lungs of Ido1 −/− mice (Fig. 5A ), even at 7 weeks postengraftment when 
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the metastatic tumor burden was high. However, a weak but signifi cant increase in kynurenine was observed in the lungs of Ido1 −/− mice (Fig. 5B) , suggesting that metastasis development may be associated with induction of an alternative mechanism of kynurenine production, such as IDO2 (24) or TDO2 (tryptophan 2,3-dioxygenase; ref. 25) , either in conjunction with or in the absence of IDO1. As in the Kras-driven primary lung tumor model, Ido1 competence in the pulmonary metastatic setting was linked to enhanced elevation of IL-6, with levels increasing up to 15-fold over baseline in WT animals (Fig. 5C ). On the other hand, the IL-6 levels in Ido1 −/− lungs remained about 2-to 4-fold over baseline even when evaluated at an extended time point to account for the differential in tumor burden (Fig. 5C ). Thus, like the autochthonous lung tumor studies, results from this lung metastasis model led us to infer a positive regulatory link between IDO and IL-6 production. Direct interrogation of this hypothesis was carried out in a cell-based assay with known IDO inducers. Lipopolysaccharide (LPS) induced both IDO activity and IL-6 production in monocytic U937 cells whereas IFN-γ on its own elicited little response but greatly elevated the level of IDO activity in combination with LPS that was mirrored by a comparable enhancement of IL-6 production (Fig. 6A) . In both instances, inclusion of the competitive IDO-inhibitory compound MTH-tryptophan (8) signifi cantly suppressed the observed increases in IDO activity as well as IL-6 production (Fig. 6A) . MTH-tryptophan-mediated suppression of IL-6 induction was confi rmed in a second monocytic cell line HL-60 (Fig. 6B) . Likewise, siRNA-mediated interference with Ido1 gene expression also signifi cantly suppressed IL-6 induction (Fig. 6C) . Taken together, these results are consistent with our in vivo fi ndings suggesting that IDO activity can potentiate the elevated production of IL-6.
IDO Drives MDSC Expansion and Immunosuppressive Function
Studies in Outcomes are representative of 6 independent experiments using TS1, clone 4, or DO11.10 transgenic T cells. E, colony-forming assays to assess the relative tumor cell burden in the lungs conducted 6 weeks following intravenous injection of 4T1 or 4T1-IL-6 cells into WT and Ido1 −/− mice. Results are presented on log scale scatter plot with means ± SEM. Signifi cance was assessed by 2-tailed Student t test at P < 0.05.
of tumor-promoting MDSCs with IL-6 serving as a critical downstream mediator of this process (26) . Because Ido1 loss attenuated IL-6 induction and metastatic colonization in the lung, we hypothesized that MDSCs may be compromised at some level in tumor-bearing Ido1 −/− mice. MDSCs isolated from WT and Ido1 −/− mice did not differ phenotypically ( Fig. 7A ; Supplementary Fig. S3A) ; however, an early delay in the expansion of Gr1
to that observed in Il1r −/− animals (26), was noted (Fig. 7B) .
Moreover, circulating MDSCs isolated from Ido1 −/− hosts were functionally impaired in their ability to suppress T cells (Fig.  7C) . We did not detect IDO1 protein in Gr1 
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obtained from tumor-bearing WT hosts ( Supplementary Fig.  S3B ), consistent with the hypothesis that the observed functional impairment of MDSCs is a non-cell-autonomous effect of IDO defi ciency in which IL-6 may act as a key intermediary.
IL-6 Is Critical to IDO-Driven MDSC Activity and Pulmonary Metastasis
To directly test the ability of IL-6 to functionally restore MDSC-suppressive activity in Ido1 −/− mice, orthotopic tumors were established using 4T1-IL-6 cells (26), a 4T1 cell population engineered to constitutively express IL-6. MDSCs isolated from Ido1 −/− mice engrafted with 4T1-IL-6 cells exhibited an elevated T-cell-suppressive activity similar to that of MDSCs isolated from WT hosts engrafted with parental 4T1 cells (Fig. 7D) . Further enhancement of MDSC-suppressive activity could be achieved by engrafting 4T1-IL-6 cells into WT mice (Fig. 7D) , indicating that the endogenous IL-6 levels stimulated by parental 4T1 tumor cells in WT animals were not fully saturating with regard to promoting MDSC suppressor function. We next asked whether restoring IL-6 levels could also reverse the metastatic resistance exhibited by Ido1 (Fig. 7E) . The proportional increase in metastatic burden observed in the 4T1-IL-6 challenged cohorts is also in line with the proposed interpretation of the MDSC functional data that IL-6 is not being produced at saturating levels in the 4T1-challenged WT animals. Because of the signifi cantly higher metastasis burden produced by 4T1-IL-6 cells, comparison of 4T1-IL-6 challenged Ido1 −/− mice to 4T1 challenged WT mice yielded a differential in mean metastatic tumor burden of only 4.8-fold (Fig. 7E) . Thus, IL-6 supplementation not only rescued WT levels of MDSC suppressor function in 4T1 tumor-challenged Ido1 −/− mice but also markedly restored their susceptibility to pulmonary metastasis development.
DISCUSSION
The idea of immune escape as a "hallmark of cancer" (28, 29) represents a groundbreaking although still largely untested paradigm within the fi eld of cancer biology. The presumption that tumors exploit IDO activity as a mechanism of immune escape, initially inferred from the pioneering studies on maternal immune tolerance of Munn and colleagues (30) , has become increasingly accepted despite a fundamental defi cit in genetic support for the role of IDO in tumor development. This study addresses this gap with direct genetic validation of the importance of IDO in well-established models of lung cancer and metastasis that offers novel insights into the impact of IDO on tumor pathogenesis. Moreover, these fi ndings strongly encourage the prioritization of clinical investigations into the use of IDO pathway inhibitors for treating lung adenocarcinomas and pulmonary metastases where more effective modalities are urgently needed.
While IDO activity was not elevated in lung tissue beyond baseline levels during KRAS-driven lung tumor development, the observed reduction in pulmonary vascularization in Ido1 −/− animals even before initiation of tumorigenesis implied that the loss of steady-state IDO in this context was suffi ciently consequential to impact physiologic processes important to tumor outgrowth. Enhanced tumor vascularization has been reported in tumor xenograft models involving exogenous IDO overexpression (31, 32) , but our study is the fi rst to identify a role for IDO in supporting vascular development under native physiologic conditions. Our fi ndings likewise genetically establish the importance of IDO activity in nontumor cells for supporting pulmonary metastasis. In this manner, IDO activity may infl uence metastatic dissemination to tissues such as the lung where its expression is particularly robust. This may, however, be less relevant when IDO [or tryptophan 2,3-dioxygenase (ref. 25) ] activity is substantially elevated within the tumor cells themselves (8, 33) , enabling the malignancy to preemptively shape its surroundings through intrinsic tryptophan catabolism. As such, IDO activity that originates from stromal cells of the tumor microenvironment or from the tumor cells themselves may contribute to directing tumor outgrowth. The positive association between IDO and IL-6 in lung tumorigenesis and metastasis was not necessarily anticipated, given that it runs counter to expectations based on IDO-mediated induction of liver-enriched inhibitory protein (LIP), a negative regulatory isoform of the Il6 gene expression promoting transcription factor C/EBPβ (24, 34) . The precise regulatory impact of LIP on Il6 expression is not clear cut, however, insofar as other fi ndings have indicated that LIP can interact with NF-κB to induce rather than limit Il6 transcription (35) . Our fi ndings are also consistent with evidence that a downstream product of IDO-mediated catabolism, kynurenic acid, can potentiate IL-6 production in the context of infl ammation by signaling through the aryl hydrocarbon receptor (36) . IL-6 is a pleiotropic cytokine that is widely implicated in supporting neoplastic outgrowth in the context of chronic infl ammation (37) . Clinically, IL-6 has been established as a marker of early relapse of resected lung tumors (38) . Analyses of DNA polymorphisms in the IL-6 promoter region have identifi ed positive correlations between IL-6 inducibility and lung cancer susceptibility in the context of concurrent infl ammatory disease (39) as well as micrometastatic disease in patients with high-risk breast cancer (40) . Functionally, IL-6 induction has been identifi ed as an essential downstream component of RAS-induced tumorigenesis (41) that is directly linked to lung tumor development in the Lox-Kras G12D transgenic mouse model (21) . Numerous other studies indicate that IL-6 can also contribute to tumor promotion by supporting angiogenesis and neovascularization of tumors (42, 43 
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the epidemiologic and functional data for IL-6 are consistent with the tumor-promoting activity that we have ascribed to IDO through mouse genetics.
Tumor responses to IDO-inhibitory compounds require functional host immunity (5, 6, 8, 9) , but the mechanisms through which IDO promotes immune escape have yet to be fully delineated. Connecting IL-6 to IDO provides valuable insight in this regard. IL-6 has previously been identifi ed in the 4T1 metastasis model as critical to the induction of MDSCs, which act as potent inhibitors of antitumor immunity (44) . MDSC accumulation is known to be driven by several factors that are produced by tumor cells and the tumor stroma, including the potent infl ammatory mediators prostaglandin E2 and IL-1β (45) (46) (47) . Genetic ablation of IL-1β signaling can affect both the early accumulation of MDSCs as well as their immunosuppressive capability (26) , and IL-6 has been determined to be a downstream mediator for the effects of IL-1β on MDSC populations in tumor-bearing animals (26) . In this context, our fi ndings identify IDO as a key determinant of IL-6-elicited MDSC accumulation and suppressor activity. Interestingly, IL-1β may dynamically potentiate the contribution of IDO to IL-6 induction given that IL-1β can promote the upregulation of IFNGR1 (48) that enhances Ido1 inducibility in response to IFN-γ. In contrast, IL-6 may exert a counter-regulatory feedback effect by inducing SOCS3 (suppressor of cytokine signaling 3), which not only attenuates IL-6 signaling (49) but also limits IDO transcription and IDO enzyme stability (50, 51) . Thus, IDO is well situated to act as a dynamic modifi er of infl ammatory states in the microenvironment of primary tumors or budding metastases.
Our results deepen the concept that IDO activity profoundly infl uences the pathogenic character of the tumor microenvironment by identifying the cytokine IL-6 as a crucial IDO effector for establishing "cancer-associated" infl ammation. IL-6 is a far-reaching, pleiotropic signaling molecule that can elicit both intrinsic and extrinsic effects on tumor development (i.e., increased malignancy and survival as well as increased angiogenesis and immune escape). The ramifi cations of our results thus extend beyond the constrained effects that local IDOmediated tryptophan catabolism might exert on the proximal microenvironment, and one would expect the potentiation of IL-6 expression by IDO to affect diverse aspects of tumor development with the relative weighting of each aspect being an important focus of future study. Indeed, further investigations of IDO as a nexus for control of tumorigenic infl ammation, vascularization, and immune escape will be invaluable in formulating rational strategies to guide the best application of IDO inhibitors that have entered clinical development.
METHODS

Transgenic Mouse Strains
Congenic Ido1
−/− mice on C57BL/6 and BALB/c strain backgrounds were provided by A. Mellor (Georgia Health Sciences University, GSHU, Augusta GA), and corresponding control strains were purchased from Jackson Laboratory. LSL-Kras G12D Cre-inducible transgenic mice on a mixed 129SvJ-C57BL/6 strain background (16) 
Micro-CT Scanning
Three-dimensional micro-CT images were acquired from anesthetized mice using an Impek Micro-CT scanner operated at 40-kVp, 500-μA, 250-millisecond per frame, 5 frames per view, 360 views, and 1-degree increments per view. Contiguous axial DICOM-formatted images through each mouse thorax, with voxels of dimensions 91 μm × 91 μm × 91 μm were compiled into 3D format using Amira v5.1 software and normalized to Hounsfi eld units. Using the segmentation editor, manual selections of the chest cavity minus the heart were conducted on every other slice followed by interpolation of these selections. Magic wand tool selection was conducted at the threshold range defi ning air (determined to be between −750 and −350) to defi ne the functional lung volume, which was automatically subtracted from the total chest space to identify the volume representing vasculature and tumors (20) .
4T1 Tumor Cell Metastasis
Parental 4T1 mouse mammary carcinoma cells and 4T1-derived cell lines expressing luciferase (4T1-luc) or mouse Il6 (4T1-IL-6) were maintained as described (5, 22, 26) . Primary tumor growth was monitored by caliper measurements of orthogonal diameters. Tumor volume was calculated using the formula for determining a prolapsed elliptoid [(d 2 × l)/0.52], where d is the shorter of the 2 orthogonal measurements. To enhance visualization of metastatic nodules, lungs were insuffl ated with India ink dye, washed, and bleached in Fekete's solution. The clonogenic assay to assess metastatic burden was conducted as described (22) .
Real-time PCR
Lung DNA was analyzed by Real Time-PCR containing SYBR green PCR master mix (Applied Biosystems) and primers to amplify Cre (5′-GGAGCCGCGCGAGATA-3′ and 5′-GCCACCAGCTTGCAT-GATC-3′) and endogenous mouse Cd81 (5′-TCGCCAAGGATGT-GAAGCA-3′ and 5′-CATTGTTGGCATCATCATCCA-3′). Assays were conducted in quadruplicate, and relative quantitation of the viral Cre gene present in lung tissue was calculated using the comparative threshold cycle (C T ) method (User Bulletin 2, Applied Biosystems) normalizing the target C T values to the internal housekeeping gene (Cd81).
Histology
Tissues were isolated and fi xed in 10% neutral-buffered formalin or 4% paraformaldehyde, sectioned, and stained for histopathologic analysis with hematoxylin and eosin using standard methods. For immunofl uorescent staining, 4-μm paraffi n sections were deparaffi nized in xylene and rehydrated with a graded alcohol series. Following antigen retrieval (vector), sections were washed and placed in 0.1% Triton for 10 minutes. Tissue was blocked in 40 μg/mL goat anti-mouse IgG-Fab (H+L) ( Vessel boundaries were identifi ed by caveolin-1 staining, and the area of every vessel within each fi eld was determined using AxioVision Release 4.6 software.
Immunoprecipitation-Western Blot Analysis
Immunoprecipitation of IDO1 protein from mouse lung tissue with purifi ed rabbit polyclonal antibody (7) followed by Western blotting-based detection with rat monoclonal antibody (clone mIDO-48; BioLegend) was carried out as described (9) .
Flow Cytometry for Cytokine and Cell Analysis
Flow cytometric data were acquired on a FACSCanto II or Cyan ADP fl ow cytometer and analyzed using FACSDIVA (BD Biosciences) or Summit v4.3.02 (Beckman/Coulter) software. Multiplexed cytokine analysis was conducted using the Infl ammation Bead Array (BD Biosciences). Lung homogenates were centrifuged and supernatant added to beads in the array according to the manufacturer's instructions. Flow cytometric analysis of MDSCs harvested from digested lung samples or from blood was conducted with the following antibodies as indicated: Gr1-FITC, Ly6G-PE, Ly6C-FITC, and CD124 (IL-4Rα)-PE (BD Biosciences); CD11b-PacB, CD115-PE, and F4/80-PE (BioLegend); Ly6C-PerCP (eBioscience); and arginase and iNOS (BD Transduction Labs). Second step goat anti-mouse IgG-Alexa 647 for arginase and inducible NO synthase (iNOS) was from Invitrogen. Isotype control antibodies were from BD Biosciences.
Kynurenine Assay
Lungs were homogenized in PBS containing dithiothreitol (DTT) and protease and phosphatase inhibitors (1:3 wt/vol). Deproteinated lysates were analyzed by high-performance liquid chromatography (HPLC) coupled to electrospray ionization liquid chromatography/ tandem mass spectroscopy (LC/MS-MS) analysis as described (9) .
Cell Culture
U937 and HL-60 monocytic cell lines (American Type Culture Collection) were expanded for frozen storage after receipt and freshly thawed cells cultured in Dulbecco's Modifi ed Eagle's Media + 10% FBS were used at early passage for experiments. No additional authentication was conducted by the authors. Twenty-four-hour treatment of cells with LPS (100 ng/mL; Sigma) and/or IFN-γ (100 ng/mL; R&D systems) was carried out in triplicate on 1 × 10 4 cells per well in a 96-well dish. MTH-Trp (methylthiohydantoin-DL-tryptophan; 100 μmol/L; Sigma) was also included at the time of induction as indicated. Kynurenine and IL-6 levels in the supernatant were analyzed as described above. Ido1 gene "knockdown" studies were conducted with siRNAs (Dharmacon) targeting Ido1 (catalog no. E-010337-00) or Gapdh (catalog no. D-001930-01) using the Accell siRNA Delivery System (Dharmacon) as described by the manufacturer. HL-60 cells were plated at 1 × 10 4 per well in a 96-well dish and cultured with 1% FBS in the Accell growth media. Twenty-four-hour treatment of cells with LPS and IFN-γ was initiated at 48 hours following incubation with siRNA. Western blotting to detect IDO1 protein in cell lysates was conducted following standard procedures using rabbit polyclonal anti-IDO1 (7) and rabbit monoclonal anti-β-actin (13E5; Cell Signaling) as a loading control. Detection was carried out with goat anti-rabbit IgG, horseradish peroxidase (HRP)-linked secondary antibody (catalog no. 7074; Cell Signaling) using the SuperSignal West Femto Chemiluminescent substrate (Thermo Scientifi c).
T-cell Suppression Assay
MDSC-suppressive activity was measured as previously described (53) 
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